German breast group study: Superior activity for nab-paclitaxel in early breast cancer
The German Breast Group study found nab-paclitaxel (ABRAXANE) demonstrates significant benefit for patients with early high-risk breast cancer when compared to conventional solvent-based paclitaxel. Nab-paclitaxel achieved a 9% absolute improvement in pathological complete response rate, outperforming traditional chemotherapy.